Responses
Clinical and epidemiological research
Extended report
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
Compose a Response to This Article
Other responses
No responses have been published for this article.